The firm also said it had a net loss of $7.9 million, or $3.50 per share, in 2014, compared to a net loss of $2.4 million, or $12.23 per share, in 2013.
The method detected differences in the vaginal microbiome that matched up with patients' clinical diagnoses of vaginosis, and also their response to antibiotic treatment.
The company is using a $3 million, three-year grant to clinically validate the test, which it hopes will be the first of its kind approved by the FDA.
In a letter to a New York court, the investor alleged that Arrayit has failed to meet the terms of a settlement that was supposed to end litigation filed last year.
Cryoport will oversee the distribution of CombiMatrix's CombiPGS preimplantantion genetic screening test for women undergoing in vitro fertilization.
In Science this week: self-assembly of DNA components in solution, and more.
Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.
A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.
With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.